Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted

This article was originally published in The Gray Sheet

Executive Summary

An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.

Advertisement

Related Content

Diagnostics A Bright Spot In Lackluster US Interventional Cardiology Market
Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel